• Targeting Protein Kinases for Cancer Therapy (dostępna w ciągu 2 tygodni)

  • Producent:John Wiley & Sons
  • Autor:M. Gerritsen
  • Kategoria:Onkologia
  • W magazynie: 0 szt.
  • Dostępność: Wysyłamy w ciągu 7 dni roboczych

data wydania    luty 2010 r.
liczba stron    702
isbn    978-0-470-22965-1
oprawa    oprawa twarda
Targeting Protein Kinases for Cancer Therapy (dostępna w ciągu 2 tygodni)



Tumor Angiogenesis From Molecular Mechanisms to Targeted The (dostępna w ciągu 2 tygodni)
519,75 zł
519,75 zł
Toksykologia narządowa
74,76 zł
93,45 zł
TNM Klassifikation Maligner Tumoren (dostępna w ciągu 2 tygodni)
131,25 zł
131,25 zł
Specialty Imaging Gynecologic Oncology (dostępna w ciągu 2 tygodni)
481,95 zł
481,95 zł
Rehabilitacja w onkologii
84,60 zł
94,00 zł
Rak szyjki macicy. Profilaktyka, diagnostyka i leczenie
103,20 zł
129,00 zł




An expert guide to targeting protein kinases in cancer therapy Research has shown that protein kinases can instigate the formation and spread of cancer when they transmit faulty signals inside cells. Because of this fact, pharma-ceutical scientists have targeted kinases for intensive study, and have been working to develop medicinal roadblocks to sever their malignant means of communication. Complete with full-color presentations, Targeting Protein Kinases for Cancer Therapydefines the structural features of protein kinases and examines their cellular func-tions. Combining kinase biology with chemistry and pharmacology applications, this book enlists emerging data to drive the discovery of new cancer-fighting drugs. Valuable information includes:

    * Comprehensive overviews of the major kinase families involved in oncology, integrating protein structure and function, and providing important tools to assist pharmaceutical researchers to understand and work in this dynamic area of cancer drug research
    * Focus on small molecule inhibitors as well as other therapeutic modalities
    * Discussion of kinase inhibitors that have entered clinical trials for the treatment of cancer, with an emphasis on molecules that have progressed to late stage clinical trials and, in a few cases, to market